A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The main goals of this Phase I study are to learn about the side effects that may occur when
everolimus and bevacizumab are given to children and young adults and to find the highest
doses of these drugs that can be given together without causing severe side effects.
Bevacizumab will be given into the vein (IV) over 30-90 minutes every two weeks and
everolimus tablets will be given daily by mouth. A cycle of therapy will be four weeks.